NewAmsterdam Pharma Company N.V.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy NewAmsterdam Pharma Company N.V. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for NewAmsterdam Pharma Company N.V. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for NewAmsterdam Pharma Company N.V. is NAMS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
NewAmsterdam Pharma Company N.V. has its primary listing on NASDAQ (Small cap). You can trade NewAmsterdam Pharma Company N.V. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, NewAmsterdam Pharma Company N.V. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include NewAmsterdam Pharma Company N.V. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like NewAmsterdam Pharma Company N.V..